Deutsche Bank AG set a €16.00 ($18.82) target price on Evotec AG (ETR:EVT) in a research note released on Monday, August 7th. The brokerage currently has a buy rating on the stock.
Separately, Berenberg Bank set a €13.00 ($15.29) price objective on Evotec AG and gave the company a neutral rating in a research report on Monday, July 31st.
Evotec AG (ETR EVT) opened at 15.479 on Monday. The firm has a 50-day moving average of €13.38 and a 200-day moving average of €10.99. The company has a market cap of €2.27 billion and a price-to-earnings ratio of 62.415. Evotec AG has a 52 week low of €4.24 and a 52 week high of €15.56.
Evotec AG Company Profile
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.
